This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the genetics of colorectal cancer. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.
Milk thistle is a plant whose fruit and seeds are used to make remedies for liver and bile duct ailments (see Question 1).
The active ingredient found in milk thistle is silymarin, an antioxidant that, among other things, protects against cell damage and stimulates repair of liver tissue (see Question 1 and Question 5).
Milk thistle has been studied in laboratory cell lines and animal tumors for its potential to make chemotherapy less toxic and more effective, and to slow the growth...
This summary is reviewed regularly and updated as necessary by the PDQ Cancer Genetics Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).
Board members review recently published articles each month to determine whether an article should:
be discussed at a meeting,
be cited with text, or
replace or update an existing article that is already cited.
Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in the published articles and determine how the article should be included in the summary.
The lead reviewers for Genetics of Colorectal Cancer are:
Kathleen A. Calzone, PhD, RN, APNG, FAAN (National Cancer Institute)
Donald W. Hadley, MS, CGC (National Human Genome Research Institute)
Jennifer Lynn Hay, PhD (Memorial Sloan-Kettering Cancer Center)
Scott Kuwada, MD, AGAF, FACP (University of Hawaii)
Patrick M. Lynch, MD, JD (University of Texas, M.D. Anderson Cancer Center)
Suzanne M. O'Neill, MS, PhD, CGC (Northwestern University)
Susan K. Peterson, PhD, MPH (University of Texas, M.D. Anderson Cancer Center)
Miguel A. Rodriguez-Bigas, MD (University of Texas, M.D. Anderson Cancer Center)
Danielle Kim Turgeon, MD (University of Michigan Comprehensive Cancer Center)
Susan T. Vadaparampil, PhD, MPH (H. Lee Moffitt Cancer Center & Research Institute)
Catharine Wang, PhD, MSc (Boston University School of Public Health)
Kevin Zbuk, MD, FRCPC (Margaret and Charles Juravinski Cancer Centre)
Any comments or questions about the summary content should be submitted to Cancer.gov through the Web site's Contact Form. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.